Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001204926 | SCV001376157 | uncertain significance | DOCK2 deficiency | 2021-04-04 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs372498181, ExAC 0.003%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with DOCK2-related conditions. This sequence change replaces isoleucine with valine at codon 464 of the DOCK2 protein (p.Ile464Val). The isoleucine residue is moderately conserved and there is a small physicochemical difference between isoleucine and valine. |
Ambry Genetics | RCV004033631 | SCV004860247 | uncertain significance | Inborn genetic diseases | 2023-11-29 | criteria provided, single submitter | clinical testing | The c.1390A>G (p.I464V) alteration is located in exon 15 (coding exon 15) of the DOCK2 gene. This alteration results from a A to G substitution at nucleotide position 1390, causing the isoleucine (I) at amino acid position 464 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |